Ruth Lupu

List of Publications by Year
in descending order

44 papers	4,963 citations	186265 28 h-index	254184 43 g-index
44 all docs	44 docs citations	44 times ranked	7711 citing authors

#	Article	IF	Citations
1	Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature Reviews Cancer, 2007, 7, 763-777.	28.4	2,355
2	Inhibition of fatty acid synthase (FAS) suppresses<i>HER2/neu</i>(<i>erb</i>B-2) oncogene overexpression in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10715-10720.	7.1	297
3	Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 1001-1016.	3.4	185
4	Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene, 2002, 21, 8178-8185.	5.9	170
5	Pharmacological Inhibitors of Fatty Acid Synthase (FASN)-Catalyzed Endogenous Fatty Acid Biogenesis: A New Family of Anti-Cancer Agents?. Current Pharmaceutical Biotechnology, 2006, 7, 483-494.	1.6	163
6	A novel CYR61-triggered â€˜CYR61-Î±vÎ²3 integrin loopâ€™ regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene, 2005, 24, 761-779.	5.9	138
7	Targeting Fatty Acid Synthase in Breast and Endometrial Cancer: An Alternative to Selective Estrogen Receptor Modulators?. Endocrinology, 2006, 147, 4056-4066.	2.8	102
8	Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. International Journal of Cancer, 2005, 115, 19-35.	5.1	100
9	Î±VÎ²3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene, 2005, 24, 3759-3773.	5.9	93
10	Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle, 2013, 12, 3109-3124.	2.6	90
11	Mediterranean Dietary Traditions for the Molecular Treatment of Human Cancer: Anti-Oncogenic Actions of the Main Olive Oils Monounsaturated Fatty Acid Oleic Acid (18:1n-9). Current Pharmaceutical Biotechnology, 2006, 7, 495-502.	1.6	88
12	Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. Current Opinion in Clinical Nutrition and Metabolic Care, 2006, 9, 346-357.	2.5	81
13	In support of fatty acid synthase (FAS) as a metabolic oncogene: Extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. Journal of Cellular Biochemistry, 2005, 94, 1-4.	2.6	77
14	Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochemical and Biophysical Research Communications, 2009, 385, 454-459.	2.1	77
15	The mitochondrial H⁺-ATP synthase and the lipogenic switch. Cell Cycle, 2013, 12, 207-218.	2.6	77
16	Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Medical Hypotheses, 2005, 64, 997-1001.	1.5	72
17	Inhibition of Tumor-associated Fatty Acid Synthase Hyperactivity Induces Synergistic Chemosensitization of HER-2/neu-Overexpressing Human Breast Cancer Cells to Docetaxel (taxotere). Breast Cancer Research and Treatment, 2004, 84, 183-195.	2.5	71
18	Pharmacological inhibition of fatty acid synthase (FAS): A novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Molecular Carcinogenesis, 2004, 41, 164-178.	2.7	71

#	Article	IF	Citations
19	Targeting Fatty Acid Synthase: Potential for Therapeutic Intervention in Her-2/neu-Overexpressing Breast Cancer. Drug News and Perspectives, 2005, 18, 375.	1.5	66
20	Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents. Current Drug Targets, 2016, 18, 147-159.	2.1	55
21	Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. Carcinogenesis, 2018, 39, 601-613.	2.8	53
22	Fatty acid synthase is required for profibrotic TGFâ€Î² signaling. FASEB Journal, 2018, 32, 3803-3815.	0.5	52
23	Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. Histology and Histopathology, 2017, 32, 687-698.	0.7	40
24	Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer. Oncotarget, 2016, 7, 71151-71168.	1.8	40
25	A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2017, 79, 1221-1227.	2.3	39
26	Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-ÎºB. International Journal of Oncology, 2004, 24, 591.	3.3	36
27	Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. Oncogene, 2004, 23, 4945-4958.	5.9	36
28	Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. Cell Death and Disease, 2021, 12, 977.	6.3	33
29	Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. Oncology Reports, 2004, 12, 411-22.	2.6	29
30	Germline <i>BRCA1</i> mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based â€œstarvationâ€•strategies in <i>BRCA1</i> carriers. Oncotarget, 2016, 7, 52974-52992.	1.8	26
31	Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer. Cancers, 2021, 13, 1132.	3.7	22
32	Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 7661.	4.1	19
33	The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells. Oncoscience, 2016, 3, 242-257.	2.2	19
34	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. Cancers, 2020, 12, 1757.	3.7	17
35	<i>BRCA1</i> haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. Oncotarget, 2017, 8, 35019-35032.	1.8	12
36	CCN1 promotes vascular endothelial growth factor secretion through Î±_vÎ²₃ integrin receptors in breast cancer. Journal of Cell Communication and Signaling, 2014, 8, 23-27.	3.4	11

#	Article	IF	Citations
37	Blockade of a Key Region in the Extracellular Domain Inhibits HER2 Dimerization and Signaling. Journal of the National Cancer Institute, 2015, 107, djv090.	6.3	10
38	Fatty acid synthase: a druggable driver of breast cancer brain metastasis. Expert Opinion on Therapeutic Targets, 2022, 26, 427-444.	3.4	10
39	Heregulin in Breast Cancer: Old Story, New Paradigm. Current Pharmaceutical Design, 2014, 20, 4874-4878.	1.9	9
40	Heregulin, a new regulator of telomere length in human cells. Oncotarget, 2015, 6, 39422-39436.	1.8	8
41	Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer. Aging, 2020, 12, 24671-24692.	3.1	6
42	Heregulin, a new interactor of the telosome/shelterin complex in human telomeres. Oncotarget, 2015, 6, 39408-39421.	1.8	5
43	Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin Î±6Î²1 drives endocrine resistance in breast cancer cells. Aging, 2022, 14, .	3.1	3
44	Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness.. American Journal of Cancer Research, 2022, 12, 839-851.	1.4	0